Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Papers
, 2021, 'Psychological outcomes in advanced cancer patients after receiving genomic tumour profiling results', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 198 - 198, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500332&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'Surveillance in multi-organ cancer predisposition', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 73 - 73, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'Cancer patient experience of uncertainty while waiting for genome sequencing results', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 23 - 24, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'How much do cancer patients value whole genome sequencing? A cross-sectional survey using the willingness-to-pay technique', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, pp. 790 - 790
, 2020, 'Psychological impact of comprehensive genomic profiling results to advanced cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 92
, 2019, 'Who should access germline genome sequencing? A mixed methods study of patient views', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 93, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Abstract 2434: Characterizing age-of-onset of multiple primary cancers and specific cancer types in families with Li-Fraumeni syndrome', in Prevention, Early Detection, and Interception, American Association for Cancer Research, pp. 2434 - 2434, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-2434
, 2019, 'Advanced cancer patient perspectives on consenting to molecular tumour profiling', in EUROPEAN JOURNAL OF HUMAN GENETICS, NATURE PUBLISHING GROUP, SWEDEN, Gothenburg, pp. 1172 - 1173, presented at 52nd Conference of the European-Society-of-Human-Genetics (ESHG), SWEDEN, Gothenburg, 15 June 2019 - 18 June 2019
, 2019, 'Characterizing age-of-onset of multiple primary cancers and specific cancer types in families with Li-Fraumeni syndrome', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-2434
, 2019, 'Translating genomic risk into an early detection strategy for sarcoma', in Genes Chromosomes and Cancer, pp. 130 - 136, http://dx.doi.org/10.1002/gcc.22697
, 2018, 'Advanced cancer patient perspectives on consenting to molecular tumour profiling: A qualitative study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 144 - 144, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200232&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'Young cancer patient perspectives on undertaking whole genome sequencing: A qualitative study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 144 - 144, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200231&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2018, 'Young cancerpatient perspectives on undertaking whole genome sequencing: A qualitativestudy', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, ITALY, Milan, pp. 722 - 723, presented at 51st Conference of the European-Society-of-Human-Genetics (ESHG) in conjunction with the European Meeting on Psychosocial Aspects of Genetics (EMPAG), ITALY, Milan, 16 June 2018 - 19 June 2018
, 2018, 'Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-2077
, 2018, 'Abstract IA03: Translating genomic risk into an early detection strategy for sarcoma', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. IA03 - IA03, http://dx.doi.org/10.1158/1557-3265.sarcomas17-ia03
Conference Posters
, 2016, 'International survey of awareness of genetic risk in the clinical sarcoma community', Vol. 12, pp. 133 - 142, http://dx.doi.org/10.1111/ajco.12457
, 2014, 'THE PSYCHOLOGICAL IMPACT OF A PILOT WHOLE-BODY SCREENING TRIAL (SMOC) ON INDIVIDUALS WITH LI-FRAUMENI SYNDROME', Vol. 10, pp. 166 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conference Abstracts
, 2026, 'HER2 mutations in advanced NSCLC: Prevalence, mutational context, and clinical outcomes from an Australian clinico-genomic database.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 44, pp. e20673 - e20673, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 29 May 2026 - 02 June 2026, http://dx.doi.org/10.1200/JCO.2026.44.16_suppl.e20673
, 2026, 'Combining implementation and data sciences to advance the speed of evidence integration into healthcare', in IMPLEMENTATION SCIENCE, BMC, Vol. 21
, 2025, 'Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, HI, Honolulu, Vol. 27, pp. v423 - v424, presented at WFNOS and SNO Annual Meeting, HI, Honolulu, 19 November 2025 - 23 November 2025, http://dx.doi.org/10.1093/neuonc/noaf201.1676
, 2025, 'PATH-52. Understanding the prevalence ofMTAP andCDKN2A/B deletion in gliomas by next generation sequencing', in Neuro-Oncology, Oxford University Press (OUP), Vol. 27, pp. v252 - v252, http://dx.doi.org/10.1093/neuonc/noaf201.1004
, 2025, '768P Operational challenges of molecular tumour board (MTBs) in the Australasian public healthcare services: A scoping survey to inform the future of precision oncology', in Annals of Oncology, Elsevier, Vol. 36, pp. s1988, http://dx.doi.org/10.1016/j.annonc.2025.10.1183
, 2025, '781P Impact of a quaternary genomics multidisciplinary team (MDT) on oncological decision-making: Pilot phase of the UNSW precision care initiative (PCI)', in Annals of Oncology, Elsevier, Vol. 36, pp. s1991 - s1992, http://dx.doi.org/10.1016/j.annonc.2025.10.1195
, 2025, '973P Phase II trial of Vismodegib in advanced cancers with Hedgehog pathway alterations', in Annals of Oncology, Elsevier, Vol. 36, pp. s637, http://dx.doi.org/10.1016/j.annonc.2025.08.1542
, 2024, 'Translating potential germline findings from tumour profiling into routine clinical care.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 42, pp. 105 - 105, http://dx.doi.org/10.1200/jco.2024.42.23_suppl.105
, 2024, 'HGG-50. LOW GRADE GLIOMA CAUGHT IN TRANSFORMATION: UTILITY OF COMPREHENSIVE GENOMIC PROFILING IN PEDIATRIC LI FRAUMENI SYNDROME ASSOCIATED HIGH-GRADE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 26, http://dx.doi.org/10.1093/neuonc/noae064.334
, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.', in Journal of Clinical Oncology, Vol. 42, pp. 1557 - 1557, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557
, 2024, 'Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board', in Journal of Clinical Oncology, American Society of Clinical Oncology, Vol. 42, presented at 2024 ASCO Annual Meeting I, 29 May 2024 - 29 May 2024, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.1557
, 2024, '1513P Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)', in Annals of Oncology, Elsevier, Vol. 35, pp. s925, http://dx.doi.org/10.1016/j.annonc.2024.08.1576
, 2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', in Annals of Oncology, Elsevier, Vol. 35, pp. s505, http://dx.doi.org/10.1016/j.annonc.2024.08.703
, 2024, 'Pattern of access to genomically-linked therapies associated with pan-cancer biomarkers in advanced cancer patients: Insights from the Australian Molecular Screening and Therapeutics (MoST) program', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 136 - 136
, 2024, 'Using Health Implementation to Integrate Precision Care - A Preliminary Analysis of a Combined Hereditary-Cancer and Medical-Oncology Clinic', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 22 - 23
, 2023, 'Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023
, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023
, 2023, 'Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023
, 2023, 'Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023
, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073
, 2022, 'Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11546 - 11546, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11546
, 2022, 'Heritable defects in telomere and mitotic function selectively predispose to sarcomas', in CANCER SCIENCE, WILEY, Vol. 113, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778583800159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2022, 'ASPiRATION: An Australian observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients. Protocol number TOGA 19/003', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 234 - 234
, 2021, 'CRESTONE: Clinical Study of REsponse to Seribantumab in Tumours with NEuregulin-1 (NRG1) Fusions: A phase 2 study of the anti-HER3 monoclonal antibody for advanced or metastatic solid tumours (MoST CRESTONE in Australia)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 206 - 206, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500346&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'My Research Results supporting researchers to return clinically actionable genetic research findings', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 36 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Advanced cancer patient preferences for receiving molecular profiling results', in Psycho Oncology, Vol. 29, pp. 1533 - 1539, http://dx.doi.org/10.1002/pon.5446
, 2020, 'Genotype and phenotype correlation of common cancer predisposition syndromes in sarcoma cases.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020
, 2020, 'Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020
, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Scientific Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 02 June 2020
, 2019, 'Exploring knowledge and attitudes in cancer tumour genomic profiling', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 194 - 195, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000493438400321&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Medical oncologists' experience with returning molecular tumor profiling to patients.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487345804031&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1